- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
- Interventions
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Biological · Other
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 17,848
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
- Conditions
- Urologic Diseases, Prostate Obstruction
- Interventions
- HoLEP
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 89 Years · Male only
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)
- Interventions
- Not listed
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 23
- States / cities
- Irvine, California • Los Angeles, California • Oakland, California + 19 more
- Conditions
- β-thalassemia Major
- Interventions
- LentiGlobin BB305 Drug Product
- Genetic
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Oakland, California • Chicago, Illinois + 1 more
- Conditions
- Scarring Alopecia, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
- Interventions
- 53-Item Survey
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Crohns Disease
- Interventions
- TRX103, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
- Conditions
- Chronic Pain, Opioids, Opioid-use Disorder
- Interventions
- I-COPE
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Infections
- Interventions
- Multidisciplinary Team, Outreach Visits, Multifaceted Intervention, Measurement and Feedback
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Charlotte, North Carolina • Greensboro, North Carolina
- Conditions
- Carcinoma, Renal Cell, Metastases, Neoplasm
- Interventions
- GTI-2040
- Drug
- Lead sponsor
- Aptose Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 10
- States / cities
- Concord, California • Los Angeles, California • Torrance, California + 7 more
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy, Conventional surgery for select patients
- Drug · Radiation · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2022
- U.S. locations
- 195
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- Panobinostat
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Breast Cancer Risk
- Interventions
- Educational video
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 25 Years to 69 Years · Female only
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-3512676
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 31
- States / cities
- Berkely, California • Gilroy, California • Hollister, California + 23 more
- Conditions
- Heart Failure
- Interventions
- Left ventricular coronary sinus (BiV) configuration, Conduction system pacing-only configuration, Conduction System Pacing Optimized Therapy (CSPOT) configuration
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Chicago, Illinois • Houma, Louisiana + 4 more
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- FEDRATINIB
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- HIV Infection
- Interventions
- GW873140
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Pumitamig, Durvalumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 38
- States / cities
- Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more
- Conditions
- Breast Cancer
- Interventions
- esterified estrogens
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Depression
- Interventions
- Behavioral intervention (iCBT + TeleCoach), Internet-based cognitive behavioral therapy (I-CBT), Treatment as usual / Wait-list control
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 488
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
- Conditions
- Kidney Transplant
- Interventions
- Berinert, Placebo for Berinert
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Other
- Eligibility
- 55 Years to 93 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Minneapolis, Minnesota + 2 more